BETHESDA, Md., Oct. 23, 2009 (GLOBE NEWSWIRE) -- Micromet, Inc. (Nasdaq:MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that it will host a conference call and audio webcast on Thursday, November 5, 2009, at 9:00 am Eastern Time (3:00 pm Central European Time) to discuss its financial results for the third quarter of 2009. Micromet anticipates releasing its financial results at 7:00 am Eastern Time (1:00 pm Central European Time) on Thursday, November 5, 2009.

To participate in this conference call, dial (877) 552-3054 (U.S.) or (706) 758-0358 (international), passcode: 37942882. The audio webcast can be accessed at www.micromet-inc.com.

The audio webcast will be available on our website from 9 am Eastern Time on Friday, November 6, 2009 (3 pm Central European Time) through Friday, February 5, 2010.

About Micromet, Inc.

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Its product development pipeline includes novel antibodies generated with its proprietary BiTE(r) antibody platform, as well as conventional monoclonal antibodies. Two of Micromet's BiTE antibodies and three of its conventional antibodies are currently in clinical trials. Micromet's preclinical product pipeline includes several novel BiTE antibodies generated with its proprietary BiTE antibody platform technology. Micromet's collaboration partners include Bayer Schering Pharma, Merck Serono, MedImmune and Nycomed.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. These forward-looking statements include statements regarding the efficacy, safety and intended utilization of our product candidates, the development of our BiTE antibody technology, the conduct, timing and results of future clinical trials, expectations of the future expansion of our product pipeline and collaborations, and our plans regarding future presentations of clinical data. You are urged to consider statements that include the words "ongoing," "may," "will," "believes," "potential," "expects," "plans," "anticipates," "intends," or the negative of those words or other similar words to be uncertain and forward-looking.